News | October 21, 2022
Aarti Drugs Q2 FY23 revenue up 19%; Profit down 5.6%
Around 62% of the revenues came from the domestic market and 38% from the exports market for Q2 FY23 for a standalone business
Around 62% of the revenues came from the domestic market and 38% from the exports market for Q2 FY23 for a standalone business
Agreement strengthens Evonik’s track record as leading contract development and manufacturing organization (CDMO)
The company increases its efficiency and is able to face the growing demand for its services.
Enriched with eight ayurvedic active ingredients like Ashwagandha, Shilajit, Shatavari, and Pippali, Be One works holistically to provide energy, build immunity and enable a healthy body and mind
This inspection continues a series of successful inspections by Swissmedic in Vionnaz with the first inspection in 2015 followed by 2016, 2017 and 2020.
Azelis’ customers now have access to products including the well-established Polyglykol portfolio, as well as a brand-new range of Motusflex and VitiPure excipients.
Blanda will be responsible for overseeing Evonik’s amino acids and functional feed additives business and the expansion of its precision livestock farming approach
Healthcare has become more focused on innovation and technology over the past two years and 80% of healthcare systems are aiming to increase their investment in digital healthcare tools in the coming five years
Her appointment further strengthens the CDMO’s strategy to become the nutraceutical R&D hub for brands looking for agile partners with large scientific and development resources
The Bulk Drug Parks to be developed under the scheme will provide common infrastructure facilities at one place thereby creating a robust ecosystem for the bulk drug manufacturing in the country and also reducing manufacturing cost significantly
Subscribe To Our Newsletter & Stay Updated
